Blood Transfusion Supplement 4 - Plasma-derived medicinal products: demand and clinical use (off subscription) (September)
Clinical use and the Italian demand for antithrombin
 
Authors:  Giancarlo M. Liumbruno, Massimo Franchini, Monica Lanzoni, Fabio Candura, Stefania Vaglio, Samantha Profili, Liviana Catalano, Giuseppina Facco, Simonetta Pupella, Gabriele Calizzani, Giuliano Grazzini
Pages:  86-93
To cite this article:  Blood Transfus 2013; 11 Suppl 4: s86-93
Doi:  10.2450/2013.014s
Published online:  08/10/2013

Preview
Introduction and notions of physiology
Antithrombin (AT) is a single-stranded glycoprotein synthesised in the liver with a plasma concentration of approximately 150 microg/mL and a molecular weight of approximately 59,000 Da1. It is a complex molecule with multiple biologically important properties. It is a serine protease inhibitor (serpin) that inactivates many enzymes in the coagulation cascade2,3. Indeed, it is the key inhibitor of the coagulation system and is estimated to provide 80% of the inhibitory activity against thrombin but it also inhibits activated factors X, IX, VII, XI, and XII. AT has a great affinity for thrombin and is also known as heparin cofactor as it is responsible for the anticoagulant effect of heparin. (...)
  
Full Text Download Back
       
Share this article: